Synageva BioPharma (GEVA) Closes $115M Comon Offering
Tweet Send to a FriendGet Alerts GEVA Hot Sheet
Down)
Trade GEVA Now!
Synageva BioPharma Corp. (Nasdaq: GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the closing of a $115 million underwritten public offering of 2,792,200 shares of common stock, including 364,200 shares of common stock which were issued pursuant to the exercise of the underwriters’ over-allotment option, at a price of $41.20 per share.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- BioLineRx (BLRX) Enters $20M ATM Offering w/ Stifel
- Cubic (CUB) Prices 2.32M Common Secondary Offering
- VIVUS (VVUS) Prices $220M Convertible Debt Offering
Create E-mail Alert Related Categories
Corporate News, Equity Offerings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
